AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	€0.5410	+1.88%	499,601
30/07/26	€0.5310	-4.67%	441,153
29/07/26	€0.5570	-2.11%	407,228
28/07/26	€0.5690	-18.48%	837,693
27/07/26	€0.6980	+36.59%	415,613

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 31/07/2026 BST			After hours 19:25:49
0.5410 ^EUR	+1.88%		0.5420	+0.18%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	42.49M 48.88M 39.55M 36.31M 68.57M 4.67B 69.63M 466M 183M 2.32B 184M 180M 7.79B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	42.49M 48.88M 39.55M 36.31M 68.57M 4.67B 69.63M 466M 183M 2.32B 184M 180M 7.79B	EV / Sales 2026 *	35.4x	EV / Sales 2027 *	32.7x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-06	AB Science S.A. Announces Board Changes	CI
07-06	AB Science S.A. Announces CEO Changes	CI
07-02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib

07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
07-13	Wall Street ne chômera pas le 14 juillet
07-10	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	+1.88%
1 week	+5.87%
Current month	-38.87%
1 month	-30.64%
3 months	-45.90%
6 months	-61.63%
Current year	-64.78%

1 week	0.52	0.7
1 month	0.5	0.78
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.65
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	06/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	19/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	31/03/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	10/07/2001
Patrick Moussy BRD	Director/Board Member	-	19/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	26/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%
02/02/21	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+1.88%	+5.87%	-63.45%	-86.54%	48.92M
MERCK & CO., INC.	+0.82%	-0.11%	+67.59%	+22.76%	321B
MERCK KGAA	+0.21%	+2.87%	+29.78%	-10.42%	71.5B
HALOZYME THERAPEUTICS, INC.	-0.95%	+0.55%	+37.37%	+91.76%	9.88B
KYOWA KIRIN CO., LTD.	-3.60%	-1.52%	-0.43%	-5.11%	8.7B
SK BIOPHARMACEUTICALS CO., LTD.	+1.80%	-0.88%	-20.84%	-3.30%	4.25B
YUHAN CORPORATION	-0.68%	+2.94%	-38.65%	+11.36%	3.86B
BETTA PHARMACEUTICALS CO., LTD.	+3.08%	-5.35%	-9.43%	+0.75%	3.47B
SUPERNUS PHARMACEUTICALS, INC.	-1.84%	-3.13%	+27.51%	+45.83%	2.65B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.85%	+5.41%	-3.94%	-4.52%	2.23B
Average	+0.16%	+1.83%	+2.55%	+6.26%	42.72B
Weighted average by Cap.	+0.60%	+4.48%	+56.07%	+17.68%

	2026 *	2027 *
Net sales	1.2M 1.38M 1.12M 1.03M 1.94M 132M 1.97M 13.17M 5.17M 65.6M 5.18M 5.07M 220M	1.3M 1.5M 1.21M 1.11M 2.1M 143M 2.13M 14.26M 5.6M 71.07M 5.62M 5.49M 238M
Net income	-	-
Net Debt	-	-